Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome ‐ not any improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ not any improvement compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ cardiovascular ‐ hypotension compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effects: specific ‐ seizure · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ central nervous system ‐ seizures compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Service utilisation: hospital admission (short term) · patients with schizophrenia
The intervention showed no clear difference in service utilisation: hospital admission (short term) (low certainty).
1 finding from 1 review
Intervention not reported
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Global state: relapse · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Mental state: clinically important change in mental state · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia (medium term) · patients with schizophrenia
The intervention showed no clear difference in adverse effect/event: clinically important extrapyramidal adverse… (low certainty).
1 finding from 1 review
Intervention not reported
Adverse effect/event: death · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Leaving the study early: any reason (medium term) · patients with schizophrenia
The intervention showed no clear difference in leaving the study early: any reason (medium term) (low certainty).
1 finding from 1 review